GlassScriptPhysician profile
Carl Jay Waldman
NPI 1750371274
$3,500.01
in general payments reported to CMS, 2019-2025
40 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $689 · 2021: $90.03 · 2022: $334 · 2023: $464 · 2024: $149 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065 · Education: $36.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.48 |
| Education | $36.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.21 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Lundbeck LLC | $214.26 | 2019-2025 | Vyepti, Rexulti |
| Allergan, INC. | $213.25 | 2019-2021 | |
| Genentech USA, INC. | $205.68 | 2019-2020 | |
| Biogen, INC. | $205.03 | 2019-2025 | Tysabri |
| Amgen INC. | $151.67 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $139.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $135.57 | 2019-2020 | |
| Ucb, INC. | $133.00 | 2019-2023 | Briviact |
| Supernus Pharmaceuticals, INC. | $116.89 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $113.12 | 2019-2020 | |
| Genzyme Corporation | $112.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $106.50 | 2019-2020 | |
| Lilly USA, LLC | $103.46 | 2019-2023 | Reyvow, Emgality |
| Sk Life Science, INC. | $95.00 | 2022-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.